Stockreport

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primar [Read more]